Avinger (NASDAQ:AVGR) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Avinger (NASDAQ:AVGR) in a report issued on Wednesday. The brokerage set a “hold” rating on the medical device company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Avinger in a report on Thursday, March 21st.

Avinger Stock Performance

Shares of NASDAQ AVGR opened at $3.85 on Wednesday. Avinger has a 1 year low of $2.50 and a 1 year high of $18.00. The stock’s 50-day simple moving average is $3.44 and its 200-day simple moving average is $3.34. The firm has a market cap of $6.12 million, a price-to-earnings ratio of -0.15 and a beta of 1.26.

Avinger (NASDAQ:AVGR) last announced its earnings results on Wednesday, March 20th. The medical device company reported ($3.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.64 by ($4.57). The business had revenue of $1.91 million during the quarter, compared to the consensus estimate of $2.52 million. As a group, research analysts predict that Avinger will post -2.08 EPS for the current year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.